Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia

ConclusionsWe propose that AML ‐M5 children with any ofMLL ‐rearrangement,FLT3 ‐ITD, hyperleukocytosis, BM blast  ≥ 70%, or age ≤ 3 years old are classified into the high‐risk group, and HSCT is beneficial especially in patients withFLT3 ‐ITD mutation, hyperleukocytosis, and age  ≤ 3 years old. Importantly, the choice of HSCT should be made more carefully in children withMLL ‐rearrangement for its suboptimal performance.

Source: Cancer Medicine - March 26, 2020 Category: Cancer & Oncology Authors: Li ‐Peng Liu, Ao‐Li Zhang, Min Ruan, Li‐Xian Chang, Fang Liu, Xia Chen, Ben‐Quan Qi, Li Zhang, Yao Zou, Yu‐Mei Chen, Xiao‐Juan Chen, Wen‐Yu Yang, Ye Guo, Xiao‐Fan Zhu Tags: ORIGINAL RESEARCH Source Type: research